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Abstract 
Although studies suggest decreased incident hepatocellular carcinoma (HCC) after treatment 
with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, data are conflicting 
regarding risk and aggressiveness of recurrence in patients who have a history of treated HCC. 
This review analyses data available in literature in order to elucidate the impact of DAAs on the 
risk of HCC recurrence after successful treatment of the tumor. Overall 24 papers were 
identified. The available data cannot be considered definitive, but the initial alarmist data 
indicating an increased risk of recurrence have not been confirmed by most subsequent studies. 
The suggested aggressive pattern (rapid growth and vascular invasion) of tumor recurrence after 
DAAs still remains to be confirmed. Several limitations of the available studies were 
highlighted, and should drive future researches. The time-to-recurrence should be computed 
since the last HCC treatment and results stratified for cirrhosis and sustained viral response. 
Any comparison with historical series is of limited interest because of a number of biases 
affecting these studies and differences between enrolled patients. Prospective intention-to-treat 
analyses will be probably the best contribution to drive clinical practice, provided that a 
randomized trial can be difficult to design.  
 
Keywords: HCV, HCC, DAA, recurrence 
 
 
Introduction 
  
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause 
of cancer-related death worldwide [1]. In the last decades, a growing incidence of HCC was 
observed in most developed countries, being hepatitis C virus (HCV)-related hepatitis one of 
the main determinant of this phenomenon [2]. The introduction of second-generation directly-
acting antivirals (DAAs) has dramatically changed the scenario of HCV infection. DAAs can 
achieve sustained virological response (SVR) rates in a percentage of cases as high as 95-98% 
[3]. Their extensive adoption is expected to lead to a progressive decrease in HCV-related HCC, 
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even if an initial cumulative increase of HCC incidence could be observed because of the lower 
risk of liver decompensation and the higher survival expectancy of cirrhotic patients with SVR 
[4-5]. 
Two contemporary retrospective studies have advanced the hypothesis that successful treatment 
with the new DAAs may be associated with higher incidence and recurrence rates of HCC [6-
7]. Moreover, an unusual increase of infiltrating tumors has been reported by these authors. 
Subsequently, controversial data have been published and several biomolecular hypotheses 
have been suggested [8]. These findings have been object of debate and could have major 
implications in the management of HCC patients. An urgent clarification is needed to drive 
clinical practice. 
This review analyses the data available in the literature in order to clarify the impact of DAAs 
on the risk of HCC recurrence after successful treatment of the tumor. 
 
Methods 
 
Literature search  
 
A systematic search of PubMed, Science Citation Index, and Embase databases was performed 
for articles published between January 2014 and January 2018 (cut-off date February 1, 2018) 
relevant to recurrence of HCC after DAAs. English language articles were selected using the 
keywords ‘hepatocellular carcinoma’, ‘HCC’, ‘HCV’, ‘DAA/directly-acting antivirals’ and 
‘recurrence’ to identify all reports that may pertain to the review issue. Manual cross-
referencing was performed, and relevant references from selected papers were reviewed. Case 
reports were excluded.  
 
Results 
 
Literature selection 
 
Overall, 24 papers (with 25 cohorts of patients) [6, 7, 9-30] reporting on HCC recurrence after 
DAAs treatment in patients with previously and successfully treated HCC (liver resection, 
ablation or trans-catheter arterial chemoembolization - TACE) were identified. Two papers only 
considered patients with HCC recurrence [25, 27], two included also patients who underwent 
liver transplantation before starting DAAs [16, 29], and one focused on radiological features of 
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recurrences [28]. The paper by Petta and coll. [12] compared the risk of HCC recurrence in 
untreated patients with the risk in patients receiving DAAs, but the paper was excluded from 
the present analysis because the data for the latter group (DAAs) were obtained from the study 
by Reig and coll. [6]. In 2016 Minami and coll. reported a time-to-event analysis on a small 
cohort of patients (n=27) [14], but they presented an updated series (n=163) [31] at the 
American Association for the Study of Liver Disease (AASLD) meeting in 2017. Both these 
data were analyzed. Calleja and coll. [9] and Bielen and coll. [16] had been contacted by the 
authors to obtain additional data about their series. Finally, a paper summarizing the abstracts 
presented at the AASLD Liver Meeting 2017 about HCC recurrence in DAAs-treated patients 
was also included in the present review [32].  
 
Recurrence risk  
 
The number of patients included in the studies ranges between 3 and 189. Most patients had 
limited disease burden at baseline, i.e. single HCC (67-94% of cases) [10, 13-15, 23, 26, 27, 29] 
< 5 cm in size (range of median size 1.8-4.7 cm) [10, 13-16, 23, 26, 27, 29] and Barcelona-
Clinic Liver Cancer (BCLC) stage 0/A (61-100% of cases) [6, 7, 10, 11, 16, 20, 23, 24, 26, 29]. 
The majority of patients underwent hepatic resection or percutaneous ablation. Only four studies 
exclusively considered patients undergoing radical treatment [14, 15, 18, 26], whereas 14 papers 
also included patients undergoing TACE or radiation treatments [6, 7, 10, 11, 13, 16, 17, 19-21, 
23, 24, 29, 31] and 4 papers did not detail the initial HCC treatment [9, 15, 22, 30]. 
Follow-up management after HCC treatment was rather homogeneous among studies (when 
detailed), being performed every 3-6 months using Computed Tomography (CT), Magnetic 
Resonance Imaging (MRI) or ultrasonography [6, 9-13, 16, 18, 23, 26, 27, 29]. 
The shortest time between last curative HCC treatment and DAAs initiation was of 0.5 months 
14. However, the mean/median time was highly variable, ranging from 2 to 21.5 months [6, 7, 
9-11, 13, 15, 16, 19, 21-23, 25-27, 29]. Three studies reported the median time between HCC 
diagnosis and DAAs treatment: 46.8 [31], 22.8 [15] and 9.6 [30] months, respectively. Five 
studies reported the median time between the last negative radiological assessment and DAAs 
therapy: 1.7 months in three studies, maximum 3 months in one and 14.4 months in one [6, 11, 
15, 19, 26]. 
The mean/median follow-up after DAAs ranged between 3 and 21.6 months [6, 7, 11, 14, 15, 
17-22, 26, 29, 31]. The proportion of HCC patients treated with DAAs that had a recurrence 
(i.e., number of events/number of patients at risk) was highly variable, ranging from 0% to 
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47.9% [6, 7, 9-11, 13-17, 19, 21-24, 29-31]. These values are not rates because they do not 
derive from time-to-event analyses. 
The data of the analyzed studies are summarized in Table 1 and in Supplementary Table 1. 
 
Time-to-event analyses 
 
Sixteen papers from 15 study groups (Minami et al. published two series), including 17 cohorts 
of patients, performed a time-to-event analysis of HCC recurrence [6, 9-11, 13-15, 17, 18, 20, 
21, 23, 24, 26, 29, 31]. In two papers, this was not explicitly reported in the manuscript, but the 
data were extrapolated from the figures [24] or the tables [17]. Regarding the paper by Reig and 
coll. [6], the time-to-event analysis performed by Cammà and coll. was considered 33. Finally, 
since Torres and coll. collected less than 10 patients and did not report recurrences, their paper 
was not considered in the review of time-to-event data [21]. The results of time-to-event 
analyses are summarized in Table 2. 
Two papers (including 3 patient cohorts) [15, 23] reported the rate of HCC recurrence per 100 
person-months ranging from 0.73 and 1.73. El Kassas and coll. reported an adjusted rate (for 
time since HCC complete radiological response, sex, age, Child-Pugh score, and history of 
gastroesophageal varices) of HCC recurrence per 100 person-months of 3.82 after DAAs 
exposure [26]. 
Twelve study groups performed a Kaplan-Meyer analysis [6, 9-11, 13-15, 17, 18, 20, 23, 24, 
31], and one paper performed a Poisson regression [26]. The time to recurrence was calculated 
in different ways: from the last HCC treatment in 8 papers [6, 9, 14, 17, 18, 20, 23, 29], from 
the initiation of DAAs therapy in 9 papers [9-11, 13, 15, 17, 20, 26, 31] and from the end of 
DAAs therapy in one study [24]. In the last two groups, the mean/median time between the last 
HCC treatment and DAAs start ranged from 8 to 21 months. 
Considering the HCC recurrence rate from the initiation of DAAs treatment, the following 
figures were reported: 9.6-23.0% at 6 months, 23.1-45.7% at 12 months, and 38.9-54.5% at 24 
months. Of note, 4 studies reported the number of patients who developed HCC recurrence 
during the DAAs treatment [6, 11, 16, 17]. 
Considering the time since the last HCC treatment, the recurrence rate was 0-7% at 6 months, 
8.7-30% at one year and 27.9-42% at two years. We plotted the available curves of recurrence 
since the last HCC treatment in a single graph (Figure 1). A recent meta-analysis by Cabibbo 
and coll. [34] theoretically provided the benchmark for HCC recurrence rate after curative 
treatments in patients with active HCV infection. However, any comparison between historical 
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data of HCC recurrence in untreated HCV patients and the present data of HCC recurrence after 
DAAs-treated patients is impossible. First, the series after DAAs are affected by an “immortal 
time” bias [35], i.e. in the DAAs group only patients without recurrence at the time of this 
treatment were considered. Further, patients receiving DAAs have high heterogeneity in terms 
of interval HCC treatment-DAAs, and type and number of treatments of HCC before DAAs.  
Nevertheless, some data about recurrence after DAAs deserve consideration. Interestingly, the 
one-year recurrence rate was significantly and inversely associated with the proportion of SVR 
achieved (p=0.008, Figure 2a): the one year after the HCC treatment. An association was also 
observed for cirrhosis: the higher the proportion of cirrhotic patients, the higher the one-year 
recurrence rate (p=0.285, Figure 2b).  
 
Comparative analyses 
 
Nine studies (10 cohorts of patients) compared the risk for HCC recurrence of DAAs treated 
patients with the risk in other populations [10-12, 14, 15, 23, 26, 29]. Before considering the 
results of these studies, the same cautionary note reported for survival analyses is mandatory. 
All comparisons of DAAs patients with historical series have poor reliability because the DAAs 
group is affected by an “immortal time” bias 35 and include heterogeneous patients (wide range 
of interval HCC treatment-DAA, mixed radical and non-radical treatments for HCC, and 
combination of first and iterative recurrences). In six studies the DAAs-treated patients were 
compared with untreated patients [10, 11, 15, 23, 26, 29]. Of these, only one paper [25] reported 
a higher recurrence rate in the DAAs group, while 3 papers (4 cohorts) reported similar figures 
[11, 15, 29] and 2 reported a low recurrence risk in DAAs patients [10, 23]. Intriguingly, one 
paper reported a similar recurrence rate between patients receiving interferon (IFN)-based and 
IFN-free treatments [18]. Two studies compared the 3 arms (DAAs, IFN-based treatment and 
untreated patients): one showed similar recurrence rates14; the second observed a significant 
reduction of tumor recurrences in successfully treated patients, without differences between 
IFN-based or IFN-free regimens groups [12].  
Considering the studies presented at the AASLD meeting in 2017, 14 abstracts analyzed the 
data of 5346 patients [32]. The risk for HCC recurrence in DAAs treated cases was unchanged 
in 8 studies (in comparison with untreated patients in 7 studies and with patients treated with 
IFN in one study) and was reduced in 3 (in comparison with untreated patients in 2 studies and 
with patients treated with IFN in one study).  
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In summary, only one paper reported an increased risk of HCC recurrence in patients treated 
with DAAs compared to untreated ones [26], and none reported an increased risk in patients 
treated with DAAs in comparison with those treated with IFN. The results of comparative 
studies are summarized in Figure 3. 
 
Predictors of recurrence 
 
Twelve studies analyzed the predictors of HCC recurrence in DAAs treated patients [6, 7, 10, 
11, 13, 17, 18, 20, 23, 26, 29, 31]. One additional paper analyzing predictors of recurrence was 
not considered because it included patients undergoing liver transplantation [16]. 
The SVR rate was one of the most commonly analyzed parameter. Its prevalence ranged 
between 62% and 100%. Nagata and coll. [18] reported that the cumulative incidence of HCC 
recurrence in patients who achieved SVR was much lower than in those without SVR (at 3 
years, 22.9% vs. 40.0%; p=0.022), but this difference was not confirmed by other authors [10, 
11, 26]. Nevertheless, as reported above, in the present review we observed a significant and 
inverse association between the SVR rate and one-year recurrence risk (Figure 2a), supporting 
the data of Nagata and coll. [18].  
The time between the last HCC treatment and DAAs start has been identified as a predictor of 
recurrence by 5 authors, i.e. the shorter the time, the higher the risk of recurrence [6, 13, 20, 29, 
31]. 
Ogawa and coll. [13] reported a higher recurrence risk (Hazard Ratio - HR 2.31 95%CI 1.04-
5.15 p=0.041) when non-curative treatments (trans-arterial therapy/radiotherapy) were adopted; 
the highest risk was observed when the time between HCC treatment and DAAs initiation was 
<1 year. Although it may be questioned whether TACE can be considered potentially curative, 
other studies did not confirm its association with HCC recurrence in patients treated with DAAs 
[6, 7, 10, 20, 23]. 
Interestingly, 4 authors [10, 11, 13, 31] observed that patients who underwent more than one 
HCC treatment before DAAs initiation had a higher recurrence rate than those treated only once 
(in the study by Ikeda and coll. 50% vs 19.1%). In agreement, Cabibbo and coll. [11] reported 
a hazard ratio of 2.22 (95%CI 1.02-4.83, p=0.043) for post-DAAs recurrence in patients with 
clinical history of prior HCC recurrence as compared to patients without prior HCC recurrence). 
The following additional predictors of HCC recurrence were reported: tumor size 11, liver 
cirrhosis 13, liver stiffness 7, patient’s age 7, 20, serum alpha-fetoprotein-L3 (AFP-L3) 31 and 
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Des-gamma-Carboxy Prothrombin (DCP) [31], anti-HBc [17], and Wisteria floribunda 
agglutinin positive Mac-2 binding protein (WFA+M2BP) [18]. 
 
Aggressiveness of recurrences 
 
Some authors speculated about a major aggressiveness of the recurrent tumor in DAAs treated 
patients [6, 10, 11, 26-28]. However, it should be noted that a definition of HCC aggressiveness 
does not exist in literature, or at least an agreement on its definition has not been reached as yet. 
Although most recurring tumor were diagnosed in BCLC stage 0 or A [6, 11, 16, 20, 22-24, 26, 
29], the authors identified as signs of HCC aggressiveness the following factors: fast tumor 
growth with a low response rate to ablation [27], percentage of infiltrative [6, 11] or multifocal 
[26] tumor pattern, and radiological signs of microvascular invasion (mVI) [28]. Specifically, 
Renzulli and coll. [28] compared the prevalence of radiological features predictive of mVI in 
HCC recurring after DAAs therapy and in tumors diagnosed before DAA treatment in the same 
patients. They showed that mVI was present in 70.7% of nodules recurred after DAAs treatment, 
a significantly higher proportion with respect to HCC detected before DAAs (33.3%, p= 
0.0007). This difference was confirmed even in the case of small nodules with a diameter 
between 10 and 20 mm. El Kassas and coll. [26] observed that 30% of patients with a recurrent 
HCC after DAAs exposure had more than three nodules vs. 18% in the DAAs non-exposed 
population with recurrence, but the limited sample size did not allow to clarify whether or not 
this difference was significant.  
Considering the studies presented at the AASLD meeting in 2017, three reported an aggressive 
pattern of recurrence after DAAs treatment and three noticed a rapid HCC recurrence [32]. 
However, a case-control study did not confirm these data because the pattern of recurrence was 
similar in patients with and without exposure to DAAs [29]. 
Recently, Critelli and coll. [36] studied, although in a non–DAAs related contest, molecular 
characteristics of the HCC aggressiveness, showing that growth speed and outcome of HCC are 
associated to specific molecular signatures of neo-angiogenesis, to prominent features of 
epithelial–mesenchymal transition with extremely poor cell differentiation, to clear-cut 
activation of transforming growth factor-beta 1 (TGF-β1) signaling and to the finding of 
programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) overexpression 
as sign of severe microenvironment immunosuppression [36]. Moreover, in a preliminary 
previous and prospective study [37], the same authors reported that 25% of new HCCs 
diagnosed under surveillance have a very rapid growth with a doubling volume time < 2 months, 
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regardless of initial BCLC classification. This fast-growing subgroup of patients can be 
biologically characterized very accurately by a 5-gene transcriptomic hepatic signature 
including angiopoietin-2 (ANGPT2), delta-like ligand 4 (DLL4), neuropilin (NRP)/tolloid 
(TLL)-like 2 (NETO2), endothelial cell-specific molecule-1 (ESM1), and nuclear receptor 
subfamily 4, group A, member 1 (NR4A1). This gene signature was associated with a worse 
prognosis (median survival of 11 vs 41 months). 
On this basis, some hypotheses have been suggested to explain the potential aggressiveness in 
the DAAs contest.  It has been assumed that a major role is played by a downregulation of the 
anti-tumor response by the immune system caused by the brutal DAAs-induced HCV clearance, 
which could boost the growth of invisible foci of malignant cells [6, 27]. It is well known that 
recurrence after a complete response to ablative treatment may be due to dissemination of cells 
before the treatment and to the appearance of new oncogenic clones within the underlying 
cirrhotic liver from already committed cells with genetic damage [38]. In fact, the viral clearance 
causes rapid downregulation of IFN stimulating genes (ISGs) in the liver and blood. The 
observed immunological changes include a down-regulation of antigen-specific T cells, with a 
restoration of proliferative HCV-specific CD8+ T cells after 12 weeks of DAA therapy in most 
SVR patients [39], and a decline of IFN-inducible protein-10 (IP-10), monocyte chemoattractant 
protein 1, macrophage inflammatory protein 1 beta and IL-18 levels [40-42]. In contrast to the 
recovery of virus-specific CD8+ T cells and natural killer (NK) cells, DAAs therapy in HCV 
patients is not followed by a restoration of the mucosal-associated invariant T (MAIT) cells 
[43]. Moreover, during DAAs therapy NK cells, which mediate target-cell apoptosis through 
surface expression of TNF-related apoptosis-inducing ligand (TRAIL), show a decrease in 
TRAIL expression [44-45]. 
According to this “immune escape hypothesis”, it can be inferred that, once HCV infection is 
cleared, small tumors already present but not radiologically evident might accelerate their 
growth. Nonetheless, it is very difficult to prove whether this mechanism is a major cause of the 
supposed greater aggressiveness of HCC recurrence.  
Finally, Carr and coll. [46] developed an HCC aggressiveness index, based on tumor diameter, 
multifocality, portal vein invasion and alpha-fetoprotein levels, which was able to stratify 
patients in 3 groups with different survival. To date, no paper reporting a potential major 
aggressiveness of HCC recurrence after DAAs adopted either the Carr and coll. index or 
homogeneous and validated criteria to define the tumor aggressiveness. A prospective study 
aimed to evaluate the recurrence pattern and the outcome of patients with recurrent HCC 
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exposed or not to DAAs treatment seems to be the only way to solve this debate and reach an 
agreement about the reliable definition of HCC aggressiveness. 
 
Management of recurrences 
 
Treatment of recurring HCCs included different approaches across studies. Ida and coll. [24] 
used curative treatments (liver resection or radiofrequency ablation) in almost all cases of 
recurrence, while in the cohort from Cabibbo and coll. [11] TACE was the most common 
treatment (45%). In the study by Abdelaziz and coll. [27] chemoembolization was adopted in 
51.1% of cases, whereas local ablation and resection were used in a minority of cases (8.9% and 
4.4%, respectively). Disease control was achieved in about half of cases (51.1%), while in one 
third of patients (33.3%) only supportive treatment was possible. Similarly, in the studies by 
Reig and coll.6 and Calleja and coll. [9] 18.7% (3/16) and 23.8% (5/21) of patients, respectively, 
were qualified for supportive care. Conversely a higher percentage of untreatable recurrence 
was reported by Bielen and coll. [16] (50%). 
 
Limitations of the available studies 
 
Several limitations of the analyzed studies should be considered. First, only 8 studies (including 
9 cohorts of patients) had a prospective design [11, 13, 15, 20-22, 26, 30], 6 of them including 
a time-to-event analysis. In addition, few papers collected an adequate number of patients (>50 
patients in 10 papers and >100 in 5) to provide reliable information. 
Second, the interval between HCC treatment and DAAs therapy, which has a crucial importance 
in setting the risk of tumor recurrence, was extremely variable. In fact, the recurrence curve 
obtained by a meta-analysis of the untreated harms of studies about HCV-patients undergoing 
curative treatment for HCC showed a parabolic shape, with the maximal risk rate over the first 
years [34]. Consequently, considering the timing of DAAs initiation, at least 3 different 
temporal scenarios with a different “intrinsic” risk can be identified (Figure 4):  
 HCC recurrence in patients exposed to DAAs within the first 3 years after successfully 
treated HCC (high risk of recurrence with a rate of 22/100py);  
 HCC recurrence in patients exposed to DAAs between 3 and 5 years after successfully 
treated HCC (intermediate risk of recurrence with a rate of 8/100py);  
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 HCC recurrence in patients exposed to DAAs 5 years after successfully treated HCC 
(low risk of recurrence with a rate of 2/100py).  
Therefore, the time to HCC recurrence should be calculated considering the last HCC curative 
treatment as the starting point. The alarmist data about high recurrence rates in DAAs treated 
patients could be simply related to the fact that DAAs were initiated in most patients during the 
period of highest recurrence risk.  
Third, 14 papers included both patients receiving potentially curative treatments (surgery and 
ablation) and palliative treatments (chemoembolization and radiation treatments) before DAAs 
therapy [6, 7, 10, 11, 13, 16, 17, 19-21, 23, 24, 29, 31]. Four papers included patients with 
multiple HCC treatments [10,11, 24, 31], while 13 papers did not detail the number of HCC 
treatments received before DAAs [6, 7, 9, 13, 15-17, 19, 21, 22, 26, 29, 30], making it difficult 
to provide solid evidence on the effect of DAAs therapy on the individual risk. 
Fourth, two main determinants of HCC recurrence should be always considered, i.e. liver 
cirrhosis and SVR. As we found in this review, both these parameters may impact recurrence 
risk. The variability of the reported recurrence rate may be therefore ascribed, at least in part, to 
the different proportion of cirrhotic patients included in the studies (range 59.2%-100%), which 
was detailed in 16 papers (with 17 cohorts of patients) [6, 7, 9, 11, 13, 15-17, 19-23, 24, 26, 29, 
30], and of the SVR rate observed (range 62%-100%), which was reported in all but two papers 
[20, 22]. Unfortunately, only few studies [10, 11, 13, 18, 20, 26] stratified the recurrence rate 
according to the presence of cirrhosis and/or the achievement of SVR. 
Finally, any comparative analysis between DAAs group and historical series suffers from at 
least one major limitation, i.e. the “immortal time” bias [35]. In fact, in the DAAs group only 
patients without recurrence at the time of this treatment were considered. A prospective 
intention-to-treat analysis, starting from the time of HCC cure and with an early DAAs initiation 
is therefore mandatory to know the real risk of cancer recurrence in patient undergoing antiviral 
treatment.  
 
Discussion 
The potential risks and benefits of DAA therapy in patients with a history of HCC are still a 
matter of debate. Some authors suggested a reduction of the recurrence risk in comparison to 
patients with untreated HCV infection, although these conclusions must be interpreted in the 
context of the clinical heterogeneity within and between studies and methodological limitations 
of current data. However, all these indirect comparisons with historical data suffer from biases 
favoring (immortal bias) or disfavoring (analyses not considering the time elapsed between 
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HCC cure and initiation of the therapy) DAAs treated patients with respect to those untreated 
or treated with IFN. Moreover, the patients may differ in term of the previous oncologic history 
and proportion of cirrhotic cases.  
Patients with a history of HCC are at risk for recurrence that can be related to intrinsic 
tumor factors and underlined liver disease such as active viremia and degree of liver function 
[47]. It has been hypothesized that the HCV eradication induced by DAAs results in reduced 
immune surveillance dysregulating the anti-tumor response and boosting the growth of still 
undetected microscopic HCC tumor clones [6, 27]. On the other hand successful antiviral 
treatment can result in fibrosis regression and improvements in portal hypertension and liver 
function, shown to be the major driver of death in patients with successfully treated HCC and 
active HCV infection [48]. In this context, DAAs may reduce risk of HCC recurrence by HCV 
eradication and liver function improvement [49]. 
The identification of factors evaluating the risk of HCC recurrence is mandatory to 
define patients subgroups in whom DAA therapy should be avoided. Several predictors for 
recurrence were reported in literature, like the history of prior HCC recurrence and the interval 
between HCC successful treatment and DAA initiation, with longer intervals being associated 
with lower risk of HCC recurrence because of a lower risk that residual tumor cells are still 
present at the DAA initiation. In this direction, some authors suggested to delay and defer DAA 
treatment till there is a well-established complete radiological response, reducing in this way 
the chance of misclassification bias [50-51]. 
An aggressive pattern (rapid growth and vascular invasion) of tumor recurrence after 
DAAs has been pointed out, but still remains to be confirmed. Most patients with HCC 
recurrence across studies were found at an early stage and underwent curative treatments, 
suggesting recurrence following DAA therapy is not aggressive; however, few data regarding 
treatment response or post-recurrence long-term prognosis are available. Considering the poor 
evidences against DAAs and the clear benefits in terms of liver function in case of SVR, the 
choice of treating these patients with antiviral drugs seems to be justified.  
The limitations of the available studies should drive future researches and avoid the 
pitfalls of several already published studies. First, time-to-event analyses are mandatory. Based 
on the “immune escape” hypothesis, the impact of DAAs therapy on tumor recurrence justifies 
the relationship between the onset of recurrence and the time elapsed since the last curative 
treatment. Therefore, it is advisable to calculate the time to recurrence considering the last HCC 
curative treatment as starting point. Further, it sounds logical to consider an interval period 
between the radiological evidence of HCC eradication and the start of DAAs to exclude the 
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presence of “prevalent” tumors, even if an agreement about the adequate duration of this time 
interval is lacking.   
Second, the proportion of cirrhotic patients and the percentage of SVR should be considered to 
properly interpret the data. The crucial contribution of these two factors to the risk of recurrence, 
even after DAAs, strengthens the hypothesis that DAAs treatment is irrelevant (or even 
protective from recurrence, according to some studies) in the natural history of HCC.  
Finally, any comparison with historical series is of limited interest because of a number of biases 
affecting these studies and differences between enrolled patients. Prospective intention-to-treat 
analyses will be probably the best contribution to drive clinical practice, provided that a 
randomized trial can be difficult to design.  
 
 
Conclusions 
The available data about the risk of HCC recurrence after DAAs treatment in HCV patients 
cannot be considered definitive, but the initial alarmist data indicating an increased risk of 
recurrence have not been confirmed by most subsequent studies. Nonetheless, since there are 
no clear evidences of a detrimental effect of DAAs on HCC recurrence, we believe that DAAs 
should not be denied to these patients, as well as, it is mandatory to maintain an active 
surveillance for HCC. 
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Figures legend 
 
Figure 1. The curves of HCC recurrence rates since the last HCC treatment of six 
different cohorts of patients treated with DAAs [6, 14, 17, 18, 20, 23] have been plotted 
in a single graph. All the curves available in the literature have been included.  
 
Figure 2. The HCC recurrence rates one year after the DAAs administration reported 
in the literature have been considered. Their association with the proportion of SVR 
achieved after DAAs and the proportion of cirrhotic patients included in the cohorts 
have been analyzed. Figure 2a shows an inverse association between the one-year 
recurrence rate and the proportion of SVR achieved after DAAs. Figure 2b shows a 
direct association between the one-year recurrence rate and the proportion of cirrhotic 
patients included in the cohorts. 
 
Figure 3. The results of studies analysing the risk of HCC recurrence in patients treated 
with DAAs in comparison with the risk of HCC recurrence in untreated patients or in 
patients receiving INF are summarized. The number of papers showing an increased, 
unchanged or decreased recurrence risk in the DAAs group vs. the no-treatment group 
(left part of the figure) or  vs. the INF group (right part) is shown .  
 
Figure 4. The HCC cumulative recurrence rate after curative treatment for HCC in 
HCV-patients without DAAs treatment is extracted from a recent meta-analysis (red 
curve) [34]. It has a parabolic shape, with the maximal recurrence risk over the first 
years. Consequently, at least 3 different temporal scenarios with a different “intrinsic” 
risk of HCC recurrence can be identified according to the timing of DAAs introduction: 
1) HCC recurrence risk in patients with the introduction of DAAs during the first 3 
years is high (22/100p/y, yellow area); 2) HCC recurrence risk in patients with the 
introduction of DAAs between 3 and 5 years is intermediate (8/100p/y, green area); 3) 
HCC recurrence in patients with the introduction of DAAs after 5 years is low 
(2/100p/y, blue area). The overall number of recurrence/100 person/year of untreated 
HCV infection have been derived from the meta-analysis by Cabibbo and coll. [34].  
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Table 1. Characteristics of the analyzed studies. 
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Table 2. Results of time-to-event analyses. 
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mo
nth
s 
12 
mo
nth
s 
18 
mo
nth
s 
24 
mo
nth
s 
Reig and 
coll.6 
NA 7% 
12.
9% 
  
 
NA 
13 pts (81.3%) new intrahepatic 
lesion: 5 pts single HCC, 4 pts ≤3 
HCC ≤3 cm, 1 pt multifocal HCC, 
3 pts infiltrative pattern and/or 
extra-hepatic lesions 
3 pts (18.7%): intrahepatic 
growth 
Calleja 
and 
coll.9 
NA  
30
% 
  
12.
9% 
30
% 
  
5/21 pts (23.8%) aggressive, 
untreatable recurrences 
Ikeda 
and 
coll.10 
NA NA 
9.6
% 
30.
1% 
 
38.
9% 
13 pts (76.5%) single HCC 
4 (23.5%) 2-3 HCC 
0% >3 HCC or with macroscopic 
vascular invasion 
Cabibbo 
and 
coll.11 
NA NA 
12
% 
26.
6% 
29.
1% 
 
62% BCLC A; 21% BCLC B; 7% 
BCLC C; 10% BCLC D 
28 pts intrahepatic growth, 24 pts 
nodular pattern, 5 pts infiltrative 
pattern, 1 pt macrovascular 
invasion 
Ogawa 
and 
coll.13 
NA NA 
1-yr in non-
cirrhotic: 6.5% 
1-yr cirrhotic: 
23.1% 
NA 
Minami 
and 
coll.14, 31 
NA  
21.
1% 
 
29.
8% 
 
38
% 
 
54.
5% 
1/78 pt (1.3%) extrahepatic 
recurrence 
Pol and 
coll. 
ANRS - 
CO22 
Hepater
15 
0.73 NA 1-yr: ≈10% †  NA 
Pol and 
coll. 
ANRS - 
CO12 
CirVir15 
1.11 NA NA NA 
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Shimizu 
and 
coll.17 
NA 0% 
8.7
% 
23.
1% 
27.
9% 
17.
4% 
45.
7% 
52.
4% 
52.
4% 
NA 
Nagata 
and 
coll.18 
NA 
5-yr: 45.1% 
3-yr SVR: 22.9%; 
3-yr no-SVR: 40% 
NA NA 
Kolly 
and 
coll.20 
NA 4% 
19
% 
 
42
% 
23
% 
42
% 
  NA 
Virlogeu
x and 
coll.23 
1.7 
≈6
% 
† 
≈13
% 
† 
≈26
% 
† 
≈31
% † 
NA NA 
Ida and 
coll.24 
NA NA 
≈2
0 ±† 
≈3
5% 
±† 
  
5 pts (42%) BCLC 0; 6 pts (50%) 
BCLC A;  
1 pt (8%) BCLC C (vascular 
invasion) 
El 
kassas 
and 
coll.26 
4.06 * NA NA 
95% of pts new site of recurrence  
30% of pts >3 HCC 
Adhoute 
and 
coll.29 
NA 
Time to 
progression: 12 
months 
NA BCLC A: 44%; B 22%; C 33% 
NA: not available 
* adjusted for covariates, † data derived from the article’s figure; ± the authors reported 
recurrence-free survival computed since the end of DAAs treatment 
 
 
 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
